Table 3.
Comparison of mucinous and serous ovarian tumors analyzed in the present study. (A) Comparison of clinicopathological features. (B) Comparison of analyzed parameters.
| Serous ovarian cancer |
Mucinous ovarian cancer |
P | ||
|---|---|---|---|---|
| Variable | No. Patients | No. Patients | ||
| A | ||||
| Age | ≤60 yrs. | 12 | 12 | 0.49 |
| >60 yrs. | 21 | 18 | ||
| FIGO stage | I/II | 5 | 10 | 0.08 |
| III/IV | 28 | 20 | ||
| Tumor grade | I/II | 22 | 24 | 0.18 |
| III | 11 | 6 | ||
| Residual disease | no | 10 | 13 | 0.21 |
| after surgery | yes | 23 | 17 | |
| Chemotherapy | no | 5 | 3 | 0.41 |
| yes | 28 | 27 | ||
| B | ||||
| Nuclear area | small (≤ median) |
20 | 14 | 0.20 |
| large (> median) |
13 | 16 | ||
| Hyperploidy | low (≤median) |
19 | 13 | 0.19 |
| high (> median) |
14 | 17 | ||
| Aneuploidy | low (≤median) |
19 | 13 | 0.19 |
| high (> median) |
14 | 17 | ||
| Proliferation index | low (≤median) |
20 | 12 | 0.08 |
| high (> median) |
13 | 18 | ||
| Chr1 Sat2 hypomethylation |
≤ score 2 | 21 | 24 | 0.12 |
| > score 2 | 12 | 6 | ||
| Chr1 Sat α hypomethylation |
≤ score 2 | 18 | 23 | 0.04 |
| > score 2 | 15 | 6 | ||
| LINE1 DNA-hypomethylation |
low (≤median) |
17 | 15 | 0.55 |
| high (> median) |
16 | 15 |
Note: The significance level (P) was determined by Chi square test.